On July 28, 2022 NeoPhore Limited, a small molecule neoantigen immuno-oncology company, reported that it has entered a three-year research collaboration agreement with Memorial Sloan Kettering Cancer Center (MSK) in New York, USA (Press release, NeoPhore, JUL 28, 2022, View Source [SID1234617111]). The objective of the collaboration is to determine the potential of NeoPhore’s proprietary DNA mismatch repair inhibitor (MMRi) compounds to enhance tumour immunogenicity and induce tumour immunity.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Building on seminal discoveries and ongoing research of its scientific founders and collaborators, NeoPhore is building a pipeline targeting novel proteins across the DNA mismatch repair (‘MMR’) pathway. The Company’s first-in-class MMR modulators alter the genotype of tumour cells to elicit increased tumour mutational burden, together with higher neoantigen presentation and tumour immunogenicity, which aim to reawaken the anti-tumour immune response and leverage sensitivity to immune checkpoint blockade.

Dr. Matthew Baker, Chief Executive Officer of NeoPhore, stated: "Collaborating with such prominent leaders in the field of applied cancer genetics is a great privilege. NeoPhore’s therapeutic concept aims to induce neoantigen creation and cancer immunity using small-molecule inhibitors of mismatch repair, particularly in combination with other immunotherapy approaches. We look forward to the outcome of this collaboration which will ultimately advance our goal to develop next-generation immuno-oncology therapeutics."